Alzheimer’s vaccine selectively targets toxic amyloid-β oligomers

April 17, 2025

Promis Neurosciences Inc. recently presented the rational design of an Alzheimer’s disease (AD) vaccine candidate maximizing the selective targeting of toxic amyloid-β oligomers.

BioWorld Science Conferences Neurology/psychiatric Vaccine

Today's news in brief

BioWorld

BioWorld briefs for Dec. 5, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 5, 2025.

Hippocratic loath? ‘Harm’ threat from ACIP’s proposed HBV shift

BioWorld

Individual liberty and choice vs. wider public health became one predictable hinge upon which swung the often-acerbic debates at the CDC’s Advisory Committee for...

Høeg appointment as acting CDER director tied to vaccine strategy?

BioWorld

After a more than 13-year period of stability with Janet Woodcock as the head of CDER, with Patrizia Cavazzoni taking charge during the next four years of former...

Illustration of chromosome unraveling down to the DNA

First phase of synthetic human genome project successfully completes

BioWorld

The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...